Comparison of shear stress-induced platelet microparticle formation and phosphatidylserine expression in presence of αIIbβ3 antagonists

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 3, 2003, Pages 363-371

  Haga, Jason H ^a,b   Slack, Steven M ^b   Jennings, Lisa K ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Glycoprotein IIb IIIa; Microparticles; Platelet antagonists; Procoagulant activity; Shear stress

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PHOSPHATIDYLSERINE; TIROFIBAN;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHEAR STRESS; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPOIESIS; THROMBOGENESIS;

BLOOD PLATELETS; CELL SIZE; GENE EXPRESSION REGULATION; HUMANS; PHOSPHATIDYLSERINES; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SHEAR STRENGTH; STRESS, MECHANICAL;

EID: 0037372547     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200303000-00004     Document Type: Article

References (44)

1. Chow TW, Hellums JD, Moake JL, et al. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood. 1992;80:113-20.
2. Oda A, Yokoyama K, Murata M, et al. Protein tyrosine phosphorylation in human platelets during shear stress-induced platelet aggregation (SIPA) is regulated by glycoprotein (GP) Ib/IX as well as GP IIb/IIIa and requires intact cytoskeleton and endogenous ADP. Thromb Haemost. 1995;74:736-42.
3. Kroll MH, Hellums JD, McIntire LV, et al. Platelets and shear stress. Blood 1996;88:1525-41.
4. Heemskerk JW, Siljander PR, Bevers EM, et al. Receptors and signalling mechanisms in the procoagulant response of platelets. Platelets. 2000;11:301-6.
5. Zwaal RFA, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 1997;89:1121-32.
6. Zwaal RFA, Comfurius P, Bevers EM. Platelet procoagulant activity and microvesicle formation: its putative role in hemostasis and thrombosis. Biochim Biophys Acta. 1992;1180:1-8.
7. Fox JEB, Austin CD, Reynolds CC, et al. Evidence that agonistinduced activation of calpain causes the shedding of procoagulantcontaining microvesicles from the membrane of aggregating platelets. J Biol Chem. 1991;266:13289-95.
8. Miyazaki Y, Nomura S, Maiyake T, et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood. 1996;88:3456-64.
9. Chow TW, Hellums JD, Thiagarajan P. Thrombin receptor activating peptide (SFLLRN) potentiates shear-induced platelet microvesiculation. J Lab Clin Med. 2000;135:66-72.
10. Holme PA, Orvim U, Hamers MJ, et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol. 1997;17:646-53.
11. Slack SM, Cui Y, Turitto VT. The effects of flow on blood coagulation and thrombosis. Thromb Haemost. 1993;70:129-34.
12. Jy W, Horstman LL, Arce M, et al. Clinical significance of platelet microparticles in autoimmune thrombocytopenia. J Lab Clin Med. 1992;119:334-45.
13. Hughes M, Hayward CP, Warkentin TE, et al. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood. 2000;96:188-94.
14. George JN, Pickett EB, Saucerman S, et al. Platelet surface glycoproteins: studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest. 1986;78:340-8.
15. Furman MI, Krueger LA, Frelinger AL 3rd, et al. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost. 2000;84:492-8.
16. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC Trial): evaluation of c7E3 Fab in the prevention of ischemic complications trial. Am J Cardiol. 1995;75:559-62.
17. Pedicord DL, Thomas BE, Mousa SA, et al. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res. 1998;90:247-58.
18. Reverter JC, Beguin S, Kessels H, et al. Inhibition of plateletmediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis."J Clin Invest. 1996;98:863-74.
19. Thomas S, Metcalfe P, Goodall AH, et al. Monoclonal antibodies against platelet membrane glycoproteins IIb/IIIa and Ibα inhibit platelet dependent thrombin generation by different mechanisms. Thromb Haemost. 2000;84:98-103.
20. Kamat SG, Turner NA, Konstantopoulos K, et al. Effects of Integrilin on platelet function in flow models of arterial thrombosis. J Cardiovasc Pharmacol 1997;29:156-63.
21. Konstantopoulos K, Kamat SG, Schafer AI, et al. Shear-induced platelet aggregation is inhibited by in vivo infusion of an antiglycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation. 1995;91:1427-31.
22. Fredrickson BJ, Turner NA, Kleiman NS, et al. Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. Circulation. 2000;101:1122-9.
23. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: the EPIC Investigation. N Engl J Med. 1994;330:956-61.
24. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. 1997;349:1429-35.
25. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med. 1998;339:436-43.
26. Kleiman NS, Lincoff AM, Flaker GC, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT investigators. Circulation. 2000;101:751-7.
27. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Qwave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study investigators). N Engl J Med. 1998;338:1488-97.
28. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized efficacy study of tirofiban for outcomes and restenosis. Circulation. 1997;96:1445-53.
29. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation. 1999;100:437-44.
30. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000;284:1549-58.
31. Jennings LK. Clinical trials of the parenteral glycoprotein IIb-IIIa inhibitors: considerations on the influence of dose selection on results. CME Certified Monographs. New York, NY: Health Science Center for Continuing Medical Education, 2001:1-44.
32. Slack SM, Jennings LK, Turitto VT. Platelet size distribution measurements as indicators of shear stress-induced platelet aggregation. Ann Biomed Eng. 1994;22:653-9.
33. Bird RB, Stewart WE, Lightfoot EN. Transport phenomena. New York: Wiley, 1960.
34. Slack SM, Turitto VT. Fluid dynamic and hemorheologic considerations. Cardiovasc Pathol. 1993;2:11S-22S.
35. Slack SM, Turitto VT. Flow chambers and their standardization for use in studies of thrombosis. Thromb Haemost. 1994;72:777-81.
36. Jennings LK, White MM. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors. Am Heart J. 1998;135:S179-83.
37. Jennings LK, Haga JH, Slack SM. Differential expression of a ligand induced binding site (LIBS) by GP IIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost. 2000;84:1095-102.
38. Glantz SA. Primer of biostatistics. New York: McGraw-Hill, 2001.
39. Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and α-granules. Blood. 1999;94:3791-9.
40. Holme PA, Solum NO, Brosstad F, et al. Microvesicles bind soluble fibrinogen, adhere to immobilized fibrinogen and coaggregate with platelets. Thromb Haemost. 1998;79:389-94.
41. Gemmell CH, Sefton MV, Yeo EL. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. J Biol Chem. 1993;268:14586-9.
42. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:188-94.
43. 1-mediated signaling pathways by fibronectin's cell adhesion and matrix assembly domains. J Cell Biol. 1998;141:241-53.
44. 3 integrin conformation and oligomerization. Biochemistry. 1999;38:14461-74.